Log in
NASDAQ:ALLO

Allogene Therapeutics Stock Forecast, Price & News

$37.02
+2.24 (+6.44 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$34.88
Now: $37.02
$37.09
50-Day Range
$32.38
MA: $35.48
$38.99
52-Week Range
$17.43
Now: $37.02
$55.00
Volume626,709 shs
Average Volume841,038 shs
Market Capitalization$5.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.67
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent. The company was founded in 2017 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALLO
CUSIPN/A
CIKN/A
Phone650-457-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.16 per share

Profitability

Net Income$-184,590,000.00

Miscellaneous

Employees122
Market Cap$5.16 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$37.02
+2.24 (+6.44 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALLO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions

How has Allogene Therapeutics' stock been impacted by Coronavirus?

Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALLO stock has increased by 47.8% and is now trading at $37.02.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Allogene Therapeutics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Allogene Therapeutics
.

When is Allogene Therapeutics' next earnings date?

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Allogene Therapeutics
.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics Inc (NASDAQ:ALLO) announced its earnings results on Wednesday, August, 5th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.01.
View Allogene Therapeutics' earnings history
.

What price target have analysts set for ALLO?

16 brokers have issued 1-year price objectives for Allogene Therapeutics' stock. Their forecasts range from $27.00 to $70.00. On average, they anticipate Allogene Therapeutics' share price to reach $47.92 in the next year. This suggests a possible upside of 29.4% from the stock's current price.
View analysts' price targets for Allogene Therapeutics
.

Who are some of Allogene Therapeutics' key competitors?

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (gild), Inovio Pharmaceuticals (INO), Teladoc Health (TDOC), Pfizer (PFE), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AbbVie (ABBV) and Crispr Therapeutics (CRSP).

Who are Allogene Therapeutics' key executives?

Allogene Therapeutics' management team includes the following people:
  • Mr. Joshua A. Kazam, Co-Founder & Director (Age 42)
  • Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS, Co-Founder & Exec. Chairman (Age 70)
  • Dr. David D. Chang M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 59)
  • Dr. Eric Thomas Schmidt Ph.D., Chief Financial Officer (Age 51)
  • Dr. Alison Moore Ph.D., Chief Technical Officer (Age 52)

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include TPG Group Holdings SBS Advisors Inc. (14.15%), Vanguard Group Inc. (4.22%), FMR LLC (2.09%), Regents of The University of California (1.02%), Victory Capital Management Inc. (0.85%) and Hillhouse Capital Advisors LTD. (0.57%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg and Veer Bhavnagri.
View institutional ownership trends for Allogene Therapeutics
.

Which major investors are selling Allogene Therapeutics stock?

ALLO stock was sold by a variety of institutional investors in the last quarter, including TPG Group Holdings SBS Advisors Inc., Regents of The University of California, FMR LLC, Capital Impact Advisors LLC, Tekla Capital Management LLC, Principal Financial Group Inc., Principal Financial Group Inc., and Man Group plc. Company insiders that have sold Allogene Therapeutics company stock in the last year include Alison Moore, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, and Veer Bhavnagri.
View insider buying and selling activity for Allogene Therapeutics
.

Which major investors are buying Allogene Therapeutics stock?

ALLO stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Victory Capital Management Inc., Hillhouse Capital Advisors LTD., Nuveen Asset Management LLC, Nordea Investment Management AB, Gilder Gagnon Howe & Co. LLC, Charles Schwab Investment Management Inc., and Blackstone Group Inc. Company insiders that have bought Allogene Therapeutics stock in the last two years include Arie Belldegrun, David D Chang, and Group Holdings (Sbs) Advis Tpg.
View insider buying and selling activity for Allogene Therapeutics
.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $37.02.

How big of a company is Allogene Therapeutics?

Allogene Therapeutics has a market capitalization of $5.16 billion. The company earns $-184,590,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Allogene Therapeutics employs 122 workers across the globe.

What is Allogene Therapeutics' official website?

The official website for Allogene Therapeutics is www.allogene.com.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-457-2700 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.